Risk-adapted Therapy for PV

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: October 18, 2021
Expiration Date: October 18, 2022

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Spivak as he discusses risk stratification and management strategies for polycythemia vera (PV). Topics include the pathophysiology and mutational foundation of PV, predicting risk and PV prognosis, current treatment strategies and controversies, and the role of targeted therapies in managing PV.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with myeloproliferative neoplasms.

Learning Objective

Upon completion of this educational activity, participants should be able to:

  • Devise treatment plans for patients with PV based on risk of thromboembolic events and patient-specific features

Agenda

Risk-adapted Therapy for PV - Jerry L. Spivak, MD, MACP

Instructions for Participation and Credit

This activity is eligible for credit through October 18, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Jerry L. Spivak, MD, MACP
Professor Emeritus-Medicine
Johns Hopkins University School of Medicine
Director
Center for the Chronic Myeloproliferative Disorders
Baltimore, Maryland

Dr. Jerry Spivak received his medical degree from Cornell University Medical College and received training in internal medicine, hematology and oncology at the Johns Hopkins Hospital, New York Hospital, and the National Cancer Institute. He is Professor Emeritus-Medicine at the Johns Hopkins University School of Medicine and the Director of the Johns Hopkins Center for the Chronic Myeloproliferative Disorders.

Dr. Spivak is board certified in internal medicine and hematology. He has held memberships in the American Clinical and Climatological Society, American Society of Hematology, International Society of Experimental Hematology, International Society of Hematology, and is a fellow of the American College of Physicians. An author of more than 250 publications, Dr. Spivak's research interests are focused on the chronic myeloproliferative disorders, with particular emphasis on the molecular basis and the means for distinguishing them diagnostically and with respect to therapeutic intervention. He has found that polycythemia vera patients can be distinguished from patients with erythrocytosis and divided into aggressive disease and a more indolent illness. Dr. Spivak and his colleagues are also studying the role of specific molecular markers with respect to the pathogenesis of polycythemia vera, as well as its diagnosis.

Accreditation

MediCom Worldwide, Inc. CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .25 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-21-037-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosure

Dr. Jerry Spivak, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.